At Verve, our goal is to disrupt the current chronic care model for cardiovascular disease with single-course gene editing medicines. Building on our mission, we believe partnering with world-class industry and academic collaborators is important to optimize the development of medicines for patients in need.
Verve has in-licensed a portfolio of gene editing and delivery technologies through strategic collaborations and licensing agreements with industry leaders, including Beam Therapeutics, the Broad Institute, Harvard University, Acuitas Therapeutics, and Novartis Pharma AG. We are also collaborating with pharmaceutical companies to develop new gene editing technologies, including with Vertex Pharmaceuticals for an undisclosed liver disease and Eli Lilly for people with atherosclerotic cardiovascular disease (ASCVD) with high blood Lp(a). In October 2023, Verve and Eli Lilly expanded their collaboration, with Lilly acquiring all of the opt-in rights to co-develop and co-commercialize Verve’s base editing programs for ASCVD, including the PCSK9 and ANGPTL3 programs previously held by Beam Therapeutics.
Through independent development of our capabilities and new technologies, Verve has established deep expertise in the research and development of gene editing medicines. We seek out and are open to exploring additional opportunities where these capabilities and our expertise can be applied to new strategic collaborations and programs.
To inquire about such opportunities, please fill out this form: